First, the conditionally active form of Cre DNA recombinase, ERT2-Cre-ERT2, enabled the regulated removal of the wild-type VHL copy in the presence of 4-hydroxitamoxifen, restoring the genetic background of the ccRCC specimen. The gene discussed is MAPK3; the disease is nonpapillary renal cell carcinoma.